Matthen Mathew

Oncology

6282 Linton Blvd
Delray Beach, FL 33484

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6 publications

INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.

INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.

Journal: Cancer immunology, immunotherapy : CII

Published: August 31, 2023

Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.

Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.

Journal: Cell reports. Medicine

Published: March 14, 2022

Extracellular Vesicles as Biomarkers in Cancer Immunotherapy.

Extracellular Vesicles as Biomarkers in Cancer Immunotherapy.

Journal: Cancers

Published: August 25, 2020

Characteristics and outcomes of lung cancer in solid organ transplant recipients.

Characteristics and outcomes of lung cancer in solid organ transplant recipients.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 07, 2020

Combining chemotherapy with PD-1 blockade in NSCLC.

Combining chemotherapy with PD-1 blockade in NSCLC.

Journal: Pharmacology & therapeutics

Published: January 22, 2018

PD-L1 as a biomarker in NSCLC: challenges and future directions.

PD-L1 as a biomarker in NSCLC: challenges and future directions.

Journal: Annals of translational medicine

Published: October 24, 2017

Showing 1-6 of 6

Last Updated: 09/26/2026